Verrica Pharmaceuticals Inc (VRCA)

$3.75

-0.25

(-6.25%)▲

Market is closed - opens 7 PM, 22 Sep 2023

Insights on Verrica Pharmaceuticals Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 37.0K → 182.0K (in $), with an average increase of 79.7% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 4 quarters, 83.0K → -10.99M (in $), with an average decrease of 2441.6% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 283.9% return, outperforming this stock by 269.0%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 452.1% return, outperforming this stock by 506.3%

Performance

  • $3.70
    $3.99
    $3.75
    downward going graph

    1.33%

    Downside

    Day's Volatility :7.33%

    Upside

    6.08%

    downward going graph
  • $2.02
    $8.70
    $3.75
    downward going graph

    46.13%

    Downside

    52 Weeks Volatility :76.78%

    Upside

    56.9%

    downward going graph

Returns

PeriodVerrica Pharmaceuticals IncSector (Health Care)Index (Russel 2000)
3 Months
-34.75%
0.0%
0.0%
6 Months
-37.21%
3.0%
-0.5%
1 Year
14.94%
7.2%
0.4%
3 Years
-54.18%
27.5%
19.1%

Highlights

Market Capitalization
194.8M
Book Value
$1.32
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-0.45
Wall Street Target Price
12.67
Profit Margin
-272.23%
Operating Margin TTM
-272.72%
Return On Assets TTM
-23.35%
Return On Equity TTM
-65.32%
Revenue TTM
8.6M
Revenue Per Share TTM
0.2
Quarterly Revenue Growth YOY
-15.0%
Gross Profit TTM
8.3M
EBITDA
-22.9M
Diluted Eps TTM
-0.45
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.21
EPS Estimate Next Year
-1.02
EPS Estimate Current Quarter
-0.21
EPS Estimate Next Quarter
-0.33

Analyst Recommendation

Buy
    83%Buy
    16%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Verrica Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 237.87%

Current $3.75
Target $12.67

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Verrica Pharmaceuticals Inc
Verrica Pharmaceuticals Inc
-8.47%
-37.21%
14.94%
-54.18%
-75.49%
Moderna, Inc.
Moderna, Inc.
-6.8%
-31.93%
-17.68%
49.48%
456.61%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-1.51%
9.46%
20.83%
45.51%
113.13%
Novo Nordisk A/s
Novo Nordisk A/s
2.93%
159.64%
287.41%
451.49%
693.95%
Seagen, Inc.
Seagen, Inc.
7.08%
3.54%
46.23%
13.76%
163.58%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
0.45%
16.4%
23.04%
33.45%
95.64%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Verrica Pharmaceuticals Inc
Verrica Pharmaceuticals Inc
NA
NA
NA
-1.21
-0.65
-0.23
0.0
1.32
Moderna, Inc.
Moderna, Inc.
39.67
39.67
0.0
-3.66
0.07
0.01
0.0
44.49
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
21.65
21.65
9.01
41.82
0.19
0.1
0.0
225.94
Novo Nordisk A/s
Novo Nordisk A/s
44.47
44.47
2.03
3.32
0.82
0.22
0.01
2.52
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-3.47
-0.26
-0.13
0.0
13.96
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.73
26.73
0.41
14.71
0.25
0.16
0.0
60.01
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Verrica Pharmaceuticals Inc
Verrica Pharmaceuticals Inc
Buy
$194.8M
-75.49%
NA
-272.23%
Moderna, Inc.
Moderna, Inc.
Buy
$39.4B
456.61%
39.67
11.33%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$90.3B
113.13%
21.65
33.93%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$423.8B
693.95%
44.47
33.4%
Seagen, Inc.
Seagen, Inc.
Hold
$38.9B
163.58%
NA
-33.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$90.9B
95.64%
26.73
35.4%

Institutional Holdings

  • Perceptive Advisors LLC

    11.98%

  • venBio Select Advisor LLC

    7.02%

  • Vanguard Group Inc

    2.91%

  • FMR Inc

    2.77%

  • BlackRock Inc

    2.39%

  • Geode Capital Management, LLC

    0.92%

Corporate Announcements

  • Verrica Pharmaceuticals Inc Earnings

    Verrica Pharmaceuticals Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

verrica pharmaceuticals inc., a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the united states. the company's lead product candidate include vp-102 that is in phase iii clinical trial for the treatment of molluscum contagiosum; in phase ii clinical trial for the treatment of common warts; and completed phase i clinical trial for the treatment of genital warts. it is also developing cantharidin-based product candidate, vp-103 for the treatment of plantar warts. the company has a license agreement with lytix biopharma as to develop and commercialize ltx-315 for dermatologic oncology indications. verrica pharmaceuticals inc. was founded in 2013 and is headquartered in west chester, pennsylvania.

Organization
Verrica Pharmaceuticals Inc
Employees
22
CEO
Mr. Ted White
Industry
Health Technology

Discover More

FAQs